No Data
Cailong Pharmaceuticals: 2024 Annual Results Forecast
Sailong Pharmaceutical Group (002898.SZ): Net income for the 2024 fiscal year is expected to decline by 31.82% to 52.80%.
On January 21, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced its performance forecast for 2024, estimating a net income attributable to shareholders of the listed company of 4.5 million yuan to 6.5 million yuan, a decrease of 31.82% to 52.80% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be 4.2 million yuan to 6.2 million yuan; the basic EPS is expected to be 0.0256 yuan/share to 0.0369 yuan/share. In 2024, the company's net income attributable to shareholders of the listed company is expected to decline year-on-year, mainly due to a decrease of approximately 11.65 million yuan in non-recurring gains and losses compared to the same period last year.
Sailong Pharmaceutical Group (002898.SZ): Received the approval notice for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient famotidine.
On January 1st, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Approval Notice for the Marketing Application of Chemical Raw Materials for Famotidine" issued by the National Medical Products Administration. Famotidine formulation is mainly used to treat upper gastrointestinal bleeding caused by digestive ulcers, as well as mucosal erosion and bleeding of the stomach and duodenum due to various causes other than tumors and esophageal or gastric varices.
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Sailong Pharmaceutical Group (002898.SZ): Sailong Polaris has cumulatively reduced its shareholding by 1%.
On November 4th, Geronghui reported that Sailong Pharmaceutical Group (002898.SZ) recently received a notification letter from shareholder Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., holding more than 5% of the shares, about the change in equity reaching 1%. It was learned that following the company's previous disclosure of the announcement of shareholders reducing their holdings by more than 1%, Sailong Juzhi reduced the company's shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, between May 4, 2023, and June 2, 2023, through centralized auction trading.
Some Confidence Is Lacking In Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) As Shares Slide 29%